Document is current

Article History

Received: 11 February 2025

Accepted: 16 April 2025

First Online: 29 May 2025

Declarations

:

: Linda Stein Gold is an investigator/advisor and/or speaker for AbbVie, Amgen, Arctis, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Kilian Eyerich has received speaker’s fees from and/or served as an advisory board member for AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Hexal, Janssen, Leo Pharma, Novartis, Pfizer, Sanofi, Sitryx, and UCB; and is a co-founder and owns shares in Dermagnostix and Dermagnostix R&D. Joseph F. Merola is a consultant and/or investigator for AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Incyte, Janssen, Leo Pharma, MoonLake, Novartis, Pfizer, Sanofi-Regeneron, Sun Pharma, and UCB. Joana Torres has received research support from AbbVie and Janssen; and has received speaker’s fees from and/or served as an advisory board member for AbbVie, Eli Lilly, Janssen, Pfizer, Sandoz, and Tillots Pharma. Laura C. Coates has received grants/research support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; worked as a paid consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MoonLake, Novartis, Pfizer, and UCB; and has been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Medac Pharma, Novartis, Pfizer, and UCB. Jessica R. Allegretti has served as a consultant for AbbVie, Adiso Therapeutics, Ferring, Finch, Iterative Scopes, Janssen, Merck, Pfizer, Roivant, and Seres Therapeutics; served as a speaker for AbbVie, Bristol Myers Squibb, and Janssen; and received research support from Janssen, Merck, and Pfizer.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.